Comparing the current results to its competitors, Valneva Se reported Revenue increase in the 4 quarter 2025 by 3 % year on year. The revenue growth was below Valneva Se's competitors' average revenue growth of 5.73 %, achieved in the same quarter.
Valneva Se's Comment on Competition and Industry Peers
The company operates in the travel vaccine industry, which is characterized by increasing competition and innovation from both new and established competitors. Some competitors, including Pfizer, possess significantly greater resources and experience, potentially affecting the company's commercial opportunities. The company is developing a Lyme disease vaccine candidate in collaboration with Pfizer, currently in Phase 3 trials and development. Strategic partnerships with Pfizer may involve relinquishing certain rights and control over product development and commercialization. Additionally, limitations in patent protection could enable competitors to develop and commercialize similar or identical products and technologies, potentially impacting the company's commercialization efforts.
March 30, 2025
Amidst Turbulent Waters: An Analysis of Valneva SE s Financial Challenges and Investor Concerns In recent developments, Pomerantz LLP has initiated an investigation on behalf of investors of Valneva SE (NASDAQ: VALN), a pharmaceutical company noted for its work in vaccine development and production. This investigation comes on the heels of significant financial downturns for the company, as reported in the fourth quarter of 2023. Investors observing this unfolding scenario should consider reaching out to Danielle Peyton at newaction@pomlaw.com or calling 646-581-9980, ext.7980, for further information. Financial Landscape and Competitor Analysis During the last quarter of 2023, Valneva SE registered a signif...
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Sources:
Valneva Se’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Valneva Se versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
